Editing
EAU & ASCO: Penile Cancer 2023
(section)
Jump to navigation
Jump to search
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== Multimodal Chemotherapy/Radiotherapy in the management of regional lymph nodes === ==== Chemotherapy ==== * Adjuvant chemotherapy ** Have a balanced discussion of risks and benefits with high-risk patients with surgically resected disease, in particular with those with pathological pelvic LN involvement (pN3) ==== Radiotherapy ==== * '''Adjuvant radiation (with or without chemo sensitisation)''' ** '''Indications''' *** '''pN2/N3 disease (including those who received prior neoadjuvant chemotherapy)''' * '''Definitive radiotherapy (with or without chemo sensitisation)''' ** '''Indications''' *** '''Patients unwilling or unable to undergo surgery''' *** '''cN3 patients who are not candidates for multi-agent chemotherapy'''
Summary:
Please note that all contributions to UrologySchool.com may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
UrologySchool.com:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Navigation menu
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Namespaces
Page
Discussion
English
Views
Read
Edit
Edit source
View history
More
Search
Navigation
Main page
Clinical Tools
Guidelines
Chapters
Landmark Studies
Videos
Contribute
For Patients & Families
MediaWiki
Recent changes
Random page
Help about MediaWiki
Tools
What links here
Related changes
Special pages
Page information